Drug-eluting stents enter periphery in U.S.
While drug-eluting stents have proved successful in repairing coronary arteries, the periphery has been more challenging. The first FDA-approved clinical trial of a drug-coated stent for a peripheral artery began in October.
The DESTINY Trial will examine the effectiveness of the Zilver PTX drug-eluting stent in the above-the-knee femoropopliteal artery. The stent, made by Cook, is self-expanding and coated with the antitumor agent paclitaxel.
The trial will initially be conducted at 10 facilities and will enroll 60 patients. The Zilver PTX stent is 8 cm long, allowing for treatment of lesions up to 7 cm. A maximum of one drug-eluting stent will be implanted per patient. The trial will allow for another Zilver bare metal stent to be used in conjunction with the Zilver PTX if there is a dissection.
Results reported earlier this year from the first phase of the SIROCCO Trial conducted in Europe showed promise for the Cordis Smart sirolimus-eluting stent in the periphery. The stent was 8 cm long and 1 to 2 mm larger than the vessel diameter (6 to 7 mm). A maximum of three stents per patient were implanted. Investigators also determined that a slow-eluting rate is better than a faster one.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
